Shanghai, China – On December 13, MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular") in-house developed Hercules™ Balloon Inflation Catheter and Reewarm™ PTA Balloon Catheter were both granted CE mark approval. It is the first CE mark approvals MicroPort® Endovascular has received, to successfully have its products registered in European Union countries, marking the first solid step to enter the European Union markets.

Hercules™ Balloon Inflation Catheter is indicated for enhancing the vessel wall apositioning after self-expandable graft-stent implantation. It can effectively enhance graft-stent expansion, avoid incomplete vessel wall apositioning, eliminate aneurysm endoleak/migration risk, and ensure precise deployment, to achieve better long-term treatment effect. Hercules™ Balloon Dilation Catheter and the aortic stent graft together provide a comprehensive solution for the endovascular stent treatment of aortic aneurysm, leading to easy and flexible operating for surgeons.

Reewarm™ PTA Balloon Catheter is designed to treat atherosclerosis-caused stenosis and occlusive disease in artery below groin, such as iliac artery, femoral artery, superficial femoral artery, popliteal artery, inferior genicular artery. It provides pre-expansion of the narrowed vascular lumen for future treatment.

The CE mark approvals of Hercules™ Balloon Inflation Catheter and Reewarm™ PTA Balloon Catheter signify the two devices' official entry in the European Union markets. With their outstanding performance, they are expected to provide better solutions for overseas patients and help MicroPort® Endovascular further expand its international market share, especially in European Union countries.